Modafinil: Difference between revisions

| brand            = Provigil (US, 100 mg and 200 mg tablets); Alertec (Canada); Modiodal (France, original market). See also: Armodafinil (Nuvigil), the R-enantiomer, a related eugeroic approved 2007 with a longer effective half-life.

| classes          = [[:Category:Eugeroics|Eugeroic (wakefulness-promoting agent)]], [[:Category:Psychostimulants|Psychostimulant]], [[:Category:Schedule IV controlled substances|Schedule IV controlled substance (US)]]

| starting_dose    = Narcolepsy/OSA: 200 mg PO once daily in the morning. Shift work disorder: 200 mg PO approximately 1 hour before the start of the work shift. Lower starting dose (100 mg) can be considered in elderly patients or those with hepatic impairment.

| preparations      = Oral tablets 100 mg and 200 mg (Provigil and generics). No IV or extended-release formulations available; compare armodafinil (Nuvigil) 50/150/250 mg tablets as the R-enantiomer alternative.

| fda_max          = 400 mg/day (though clinical trials and FDA label note that doses above 200 mg/day have not demonstrated additional benefit in controlled studies for the approved indications; 200 mg is the standard therapeutic dose).<ref name="provigil-label">FDA Prescribing Information, Provigil (modafinil) Tablets, Cephalon/Teva, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020717s037lbl.pdf</ref>

| routes            = Oral only.

| onset            = Peak plasma concentrations 2-4 hours after oral dose. Wakefulness-promoting effect onset correlates with peak plasma; subjective alertness typically reported within 1-2 hours of dosing.

| duration          = Effective wakefulness promotion through approximately 12-15 hours reflecting the half-life of the predominant R-enantiomer. For shift-work use, 200 mg taken 1 hour before shift provides coverage through most 8-12 hour shifts.

| halflife          = The racemic mixture of modafinil has an effective half-life of approximately 12-15 hours due to differential enantiomer kinetics: the R-enantiomer (R-modafinil) has a half-life of ~15 hours; the S-enantiomer has a half-life of ~4 hours. In practice, the R-enantiomer dominates steady-state pharmacology, giving a 12-15h effective duration.<ref name="provigil-label" />

| bioavailability  = Approximately 80% (well-absorbed orally; not significantly affected by food, though food may delay Tmax by ~1 hour).<ref name="provigil-label" />

| pregnancy        = EMA pregnancy prevention program required as of 2019 (significant congenital malformation signal from observational registry data; see pregnancy_details). FDA labeling updated to reflect human data concerns. Modafinil should be considered contraindicated or avoided in pregnancy unless the clinical need is compelling and the patient has been counseled. Females of reproductive potential must use effective non-hormonal contraception during treatment and for 2 months after discontinuation (hormonal contraceptive efficacy is reduced by modafinil; see interactions).

| legal            = [[USLegal:Schedule IV|Schedule IV controlled substance (US)]]. Rx-only. The DEA scheduled modafinil as Schedule IV in 1999, reflecting confirmed abuse potential (dopamine reward pathway activity) but substantially lower abuse liability than Schedule II stimulants (amphetamine, methylphenidate). Available as generic modafinil (widely) since 2012 US patent expiry.

| mechanism        = <vote slug="modafinil-mech-claim">Modafinil's mechanism of wakefulness promotion is incompletely understood but is best characterized as a '''dopamine transporter (DAT) inhibitor''' that increases synaptic dopamine concentrations primarily through reuptake inhibition rather than dopamine release. This distinguishes it mechanistically from amphetamines and methylphenidate, which cause dopamine efflux via reverse transport; modafinil binds the DAT but does not significantly trigger reverse transport, resulting in a more gradual and sustained dopamine elevation with lower abuse liability.<ref name="wisor-2001">Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci. 2001;21(5):1787-1794. PMID 11222668.</ref>

Secondary mechanisms contributing to wakefulness include norepinephrine transporter (NET) inhibition (elevating noradrenergic tone), activation of orexin/hypocretin-containing neurons in the lateral hypothalamus (the same neurons lost in narcolepsy type 1), and increased histaminergic signaling (H1 activation, consistent with wakefulness -- the inverse of H1-blocking antihistamines that cause drowsiness). Serotonin and GABA effects have been described but are considered secondary to the dopamine/norepinephrine and histamine effects.</vote>

| intro            = Modafinil is a wakefulness-promoting agent (eugeroic) used primarily for narcolepsy, obstructive sleep apnea residual sleepiness, and shift work sleep disorder. It is chemically unrelated to amphetamines and is mechanistically distinct from classical psychostimulants, acting primarily as a dopamine reuptake inhibitor without significant dopamine release, which accounts for its Schedule IV (rather than Schedule II) classification and its comparatively modest abuse liability. It is nonetheless a controlled substance with demonstrated dopamine reward-pathway activity.

Modafinil was developed at Laboratoire Lafon in France by researcher Michel Jouvet's group in the 1970s-1980s as a refinement of adrafinil, a prodrug in the same benzhydryl sulfinyl compound series that Lafon had developed for sleepiness in elderly patients. Modafinil is the active sulfoxide metabolite of adrafinil and was found to have superior potency and reduced peripheral side effects. It was approved in France in 1994 under the trade name Modiodal and received FDA approval in the US in 1998 (Provigil) for narcolepsy, with label expansions to obstructive sleep apnea residual sleepiness and shift work sleep disorder in 2003. Cephalon (later acquired by Teva Pharmaceuticals) marketed Provigil in the US until generic entry in 2012.

The R-enantiomer of modafinil, armodafinil (Nuvigil, approved by FDA in 2007), has a longer effective half-life (~15 hours) than racemic modafinil (~12-15 hours overall) and was developed as an improved once-daily formulation. Racemic modafinil and armodafinil are considered therapeutically interchangeable for the approved indications at equivalent doses (150 mg armodafinil is approximately bioequivalent to 200 mg modafinil).

Off-label use of modafinil for cognitive enhancement in healthy individuals became prominent in the 2000s through patient-advocacy networks and media attention, contributing to supply pressures and diversion concerns. The emergence of modafinil as a "smart drug" was not supported by robust trials showing benefit in non-sleep-deprived healthy subjects, though sleep-deprivation-reversal effects are well-established.

A significant pregnancy safety signal was identified in European registry data (congenital malformations), leading the EMA to impose a mandatory pregnancy prevention program in 2019, substantially restricting modafinil prescribing in Europe for women of childbearing potential.

| history          = Modafinil's history begins with adrafinil, a benzhydryl sulfinyl compound synthesized at Laboratoire Lafon in France in the late 1970s as part of a research program into vigilance-promoting compounds led by the neurobiologist Michel Jouvet. Adrafinil was found to promote wakefulness in animals and humans and was approved in France in 1986 (Olmifon) for treatment of sleepiness and hypersomnia in elderly patients.{{citation needed}}<!-- Candidate: Jouvet M historical sources; Lafon pharmaceutical records. The Jouvet attribution is well-established in secondary sources but primary-source year and institutional credit need verification. -->

Modafinil, the active sulfoxide metabolite of adrafinil, was identified and developed as a standalone compound in the 1980s, offering the advantage of direct activity without requiring hepatic conversion and with a cleaner side-effect profile. Modafinil was approved in France in 1994 under the trade name Modiodal for narcolepsy. The FDA approved modafinil (Provigil) in the United States in December 1998 for narcolepsy. In 2003, FDA expanded the label to include obstructive sleep apnea residual sleepiness (as an adjunct to CPAP) and shift work sleep disorder.

The DEA placed modafinil in Schedule IV in 1999 following confirmation of dopamine reward-pathway activity and evidence of human abuse and diversion, though the relative abuse potential is substantially lower than Schedule II agents. Studies using PET imaging confirmed modafinil's dopamine transporter occupancy at therapeutic doses and its ability to elevate dopamine in the nucleus accumbens, establishing the mechanism basis for scheduling.<ref name="volkow-2009">Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301(11):1148-1154. PMID 19293415.</ref>

In 2006, FDA declined to approve modafinil for pediatric ADHD, citing serious skin reaction (SJS/TEN and DRESS) risk in children. This decision, despite positive efficacy data, significantly limited modafinil's pediatric market and reinforced amphetamine-class agents as the standard of care for ADHD.

Cephalon obtained a US patent for modafinil and aggressively extended patent protection through formulation changes, leading to FTC scrutiny and ultimately generic entry beginning in 2012 after patent litigation settlements. Armodafinil (Nuvigil), the R-enantiomer, was approved by FDA in June 2007 as an improved formulation with longer duration of action, extending Cephalon's market position.

A 2019 assessment by the EMA (European Medicines Agency) identified a risk of congenital malformations in pregnancies exposed to modafinil, based on observational registry data showing higher rates of congenital cardiac malformations and other structural anomalies in exposed pregnancies compared to unexposed controls.{{citation needed}}<!-- Candidate: EMA assessment report on modafinil, 2019; EMA/CHMP/688655/2019 or equivalent reference number. The EMA action in 2019 restricting modafinil in women of childbearing potential is well-documented in the medical literature and EMA public communications; specific registry PMID for underlying data needs verification. --> The EMA required a pregnancy prevention program (similar in structure to the valproate pregnancy prevention program) and restricted modafinil prescribing in women of childbearing potential to those who meet contraception requirements. The FDA updated US labeling to reflect the human data signal.

| indications      = <problem ref="narcolepsy" author="parser-claude">Narcolepsy (type 1 and type 2); reduces excessive daytime sleepiness. FDA-approved first-line pharmacotherapy. Does not address cataplexy (the hallmark of type 1 narcolepsy); sodium oxybate, pitolisant, or tricyclic antidepressants are used for cataplexy management.</problem>

200 mg PO once daily in the morning. Most patients respond to 200 mg. Doses above 200 mg have not shown consistent additional benefit in controlled trials for the approved indications and increase adverse effect burden.

Elderly patients and those with severe hepatic impairment (Child-Pugh C): consider 100 mg/day starting dose.

For patients with OSA: confirm CPAP use and adherence before prescribing; modafinil does not substitute for CPAP and does not reduce the cardiovascular or respiratory consequences of untreated OSA.

<titration slug="shift-work" author="parser-claude" title="Shift work sleep disorder">

200 mg PO approximately 1 hour before the start of the work shift. Timing is important; taking modafinil too late in the shift may cause difficulty sleeping after work. Not recommended for episodic shift changes; most appropriate for regular shift schedules.

<titration slug="off-label-fatigue" author="parser-claude" title="Off-label: MS/cancer-related fatigue">

100-200 mg PO once daily in the morning, titrated to effect. Evidence base for MS-related fatigue is inconsistent; some trials positive, some null. Cancer-related fatigue evidence is mixed; most benefit suggested in patients with significant fatigue burden (FACIT-Fatigue scales). Use as trial therapy with explicit assessment endpoints; discontinue if no clear benefit at 4-6 weeks.

</titration>

* <effect ref="insomnia" author="parser-claude">Particularly if taken too late in the day; the 12-15h half-life means afternoon dosing can interfere with nighttime sleep. Counsel on timing (morning dose for narcolepsy/OSA).</effect>

* <effect ref="sjs-dress" author="parser-claude">Rare but serious: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). The most serious safety concern; the basis for FDA's 2006 rejection of pediatric ADHD indication. Any rash, especially with mucosal involvement or systemic features, requires immediate discontinuation and evaluation. Risk appears higher in children than adults.</effect>

* <effect ref="reduced-contraceptive-efficacy" author="parser-claude">CYP3A4 induction reduces the systemic exposure of hormonal contraceptives (ethinyl estradiol, progestins). See Interactions. Clinically important for reproductive counseling.</effect>

* <effect ref="appetite-suppression-weight-loss" author="parser-claude">Mild appetite suppression; less prominent than amphetamine-class agents. Generally not clinically meaningful but can be useful in some patients and concerning in those with low body weight or eating disorder history.</effect>

* <effect ref="abuse-dependence" author="parser-claude">Schedule IV; confirmed dopamine reward-pathway activity. Abuse and psychological dependence have been reported, particularly in individuals with stimulant use disorder histories. However, abuse potential is substantially lower than Schedule II stimulants.</effect>

| pk_absorption    = Oral bioavailability approximately 80%; well-absorbed from the GI tract. Peak plasma concentrations (Tmax) at 2-4 hours after dosing. Food does not significantly alter overall bioavailability but may delay Tmax by approximately 1 hour and reduce peak concentration modestly; clinically not significant for most patients.<ref name="provigil-label" />

| pk_distribution  = Volume of distribution approximately 0.9 L/kg. Plasma protein binding approximately 60% (primarily albumin). Distributes widely into brain tissue; CNS penetration is required for therapeutic effect and is confirmed by PET studies showing DAT occupancy at therapeutic doses.<ref name="provigil-label" />

| pk_metabolism    = Modafinil undergoes primarily hepatic metabolism. The major pathway is amide hydrolysis to modafinil acid (major inactive metabolite, renally excreted) and to a lesser extent modafinil sulfone (minor inactive metabolite via CYP3A4/3A5). Approximately 90% of the dose is recovered as metabolites; less than 10% is excreted as unchanged parent compound.

Critically for drug interactions: modafinil is a moderate inducer of CYP3A4 and CYP2C9 (relevant for contraceptives, cyclosporine, and statin interactions) and an inhibitor of CYP2C19 (relevant for warfarin, phenytoin, diazepam, and some TCAs). CYP1A2 is also moderately induced.

Modafinil exhibits non-linear PK with repeated dosing due to autoinduction of CYP-mediated elimination pathways; steady-state plasma concentrations are lower than predicted from single-dose data, and steady state is typically reached within 2-4 days.<ref name="provigil-label" />

| pk_elimination    = Primarily renal elimination of metabolites (~80%); fecal route accounts for the remainder. Half-life of the racemic mixture approximately 12-15 hours at steady state (R-enantiomer ~15h, S-enantiomer ~4h). Hepatic impairment (severe) reduces clearance significantly; dose reduction required. Renal impairment does not significantly affect parent drug clearance but metabolites accumulate; caution in severe renal impairment. Not significantly dialyzed.<ref name="provigil-label" />

| pharmacodynamics  = Modafinil's primary pharmacodynamic effect is promotion of wakefulness via dopamine transporter inhibition with consequent increase in synaptic dopamine. PET imaging studies at therapeutic doses have demonstrated significant DAT occupancy (approximately 50-70% occupancy at 200 mg) in the human caudate and putamen, with corresponding elevations in synaptic dopamine in the nucleus accumbens and striatum, confirming that the dopamine pathway is engaged at clinical doses.

The key distinction from amphetamines is the absence of significant dopamine efflux: modafinil inhibits reuptake but does not cause the vesicular dopamine release or reverse transport that characterizes amphetamine action. This difference in mechanism produces a more gradual, sustained dopamine increase rather than the sharp spike-and-crash profile of amphetamines and is the pharmacodynamic basis for modafinil's lower abuse liability and Schedule IV rather than Schedule II classification.

Norepinephrine reuptake inhibition (via NET) contributes to wakefulness and alertness and may account for some of the sympathomimetic cardiovascular effects (modest BP and HR increases).

Orexin/hypocretin neuron activation is relevant to the narcolepsy indication: type 1 narcolepsy involves loss of orexin-producing neurons in the lateral hypothalamus. While modafinil cannot replace lost orexin neurons, dopaminergic activation may engage downstream arousal circuitry and partially compensate for orexin deficiency. Whether modafinil acts directly on orexin receptors or indirectly via dopamine is debated.

Histamine H1 pathway activation (elevated histaminergic tone) contributes to wakefulness; this mechanism is consistent with the inverse effect of H1 antihistamines.

| interactions      = <pharmaInteractions/>

Clinically important interactions for prescribers:

* '''Hormonal contraceptives (oral and implantable).''' Modafinil is a CYP3A4 inducer and substantially reduces systemic exposure of ethinyl estradiol and progestin components of combined hormonal contraceptives. This is a MANDATORY counseling point: patients using hormonal contraceptives (pill, patch, ring, implant) should be counseled to use a non-hormonal barrier method during modafinil treatment and for 2 months after stopping. This applies to combined hormonal contraceptives; hormonal IUDs (which act locally in the uterus) are less affected, but the package insert recommends consultation regardless.<ref name="provigil-label" />

* '''CYP2C19 substrates.''' Modafinil inhibits CYP2C19 and increases exposure of:

  - Warfarin: INR should be monitored more frequently at initiation and with dose changes

  - Phenytoin: phenytoin levels may increase; monitor and consider level check

  - Diazepam: increased diazepam exposure; reduce diazepam dose if co-prescribed

  - Clomipramine and other CYP2C19-metabolized TCAs: increased TCA levels

* '''CYP3A4 substrates (induction risk).''' Modafinil modestly induces CYP3A4 and may reduce efficacy of:

  - Cyclosporine: significant interaction; cyclosporine levels should be monitored in transplant patients

  - Some HIV antiretrovirals (PIs and NNRTIs metabolized by CYP3A4)

  - Statin interactions are generally modest but theoretically possible

* '''Methylphenidate and amphetamines.''' Co-prescribed for ADHD or treatment-resistant sleepiness: additive wakefulness effects. Additive cardiovascular stimulant effects. Not a strict contraindication but caution warranted.

* '''MAOIs.''' Theoretical concern from combined dopaminergic/adrenergic activity. Avoid combination or observe carefully with appropriate washout between agents.

* '''Clozapine.''' Modafinil is a CYP1A2 inducer and clozapine is primarily a CYP1A2 substrate; the expected pharmacokinetic direction is reduced clozapine exposure, with risk of breakthrough psychosis or loss of clozapine efficacy (not clozapine toxicity). Case reports of clinically significant clozapine level changes with modafinil co-administration have been reported; monitor clozapine levels and clinical status if modafinil is added or discontinued in a patient on clozapine.{{citation needed}}<!-- Candidate: modafinil-clozapine interaction case reports in the literature; direction of effect via CYP1A2 induction predicts clozapine REDUCTION. Specific PMIDs not confirmed; flag for verification. -->

| pregnancy_details = A 2019 EMA pharmacovigilance review of registry and observational data identified a statistically significant increase in congenital malformations (particularly congenital cardiac malformations and oro-facial malformations) in pregnancies exposed to modafinil compared to unexposed controls. The absolute risk increase was modest but the signal was sufficient for the EMA to require a mandatory pregnancy prevention program, restricting modafinil to females of reproductive potential who fulfill contraception requirements and undergo regular pregnancy testing.{{citation needed}}<!-- Candidate: EMA product-information update document; PMID for the underlying registry study (likely European EURAP or similar dataset); specific PMID not confirmed. EMA action in 2019 is well-documented in public-domain EMA communications. -->

The FDA updated US prescribing information to include the human pregnancy signal and requires counseling about the risk. The FDA has not required a formal pregnancy prevention program comparable to the EMA's, but the updated labeling recommends that females of reproductive potential use effective contraception.

Animal studies at high doses identified skeletal malformations and intrauterine growth restriction in rats and rabbits; developmental effects were seen at doses producing maternal toxicity.

- Modafinil should generally be avoided in pregnancy unless the clinical need (e.g., uncontrolled narcolepsy with significant safety implications) outweighs the documented congenital malformation risk

- If continuing in pregnancy, specialist consultation and close fetal monitoring are appropriate

- Abrupt discontinuation in narcoleptic patients may pose safety risks (e.g., sudden sleep onset while driving); a managed transition plan is needed

Breastfeeding: Limited human data on transfer into breast milk. Animal studies suggest some transfer. Given the lack of safety data and the availability of non-pharmacologic strategies for maternal sleepiness management (where feasible), avoidance during breastfeeding is generally recommended.{{citation needed}}<!-- Candidate: LactMed NCBI entry for modafinil; specific milk-transfer data limited. -->

| monitoring        = Baseline before initiation:

* Blood pressure and heart rate (modest cardiovascular stimulant; baseline needed for comparison)

* Skin: no routine testing, but counsel about SJS/DRESS at initiation -- any rash requires prompt evaluation

* Drug interactions review: warfarin (INR), phenytoin (levels), cyclosporine (levels), hormonal contraceptives (switch to non-hormonal)

* Hepatic function: modafinil is primarily hepatically metabolized; severe hepatic impairment requires dose reduction and closer monitoring

* Blood pressure at follow-up visits, especially in hypertensive patients

* Efficacy assessment: daytime sleepiness scales (Epworth Sleepiness Scale, Maintenance of Wakefulness Test in some settings); response should be documented

* Monitor for psychiatric symptoms (agitation, psychosis, mania) especially in first weeks of treatment

* No routine CBC, metabolic, or LFT monitoring required in uncomplicated patients

| counseling        = '''Take in the morning (narcolepsy/OSA).''' Modafinil lasts 12-15 hours; taking it in the afternoon can prevent you from sleeping at night. For narcolepsy and OSA, morning dosing gives you daytime coverage without disrupting nighttime sleep.

'''Rash: stop and call us.''' Modafinil can rarely cause a severe skin reaction (Stevens-Johnson syndrome or DRESS). If you develop any rash, especially one involving your mouth, eyes, or genitals, or accompanied by fever or swollen lymph nodes, stop the medicine and contact us the same day.

'''Driving.''' Modafinil is used to treat sleepiness, but it does not completely eliminate the risk of sudden sleep onset, especially if narcolepsy is not fully controlled. Discuss driving safety with your prescriber.

'''Not a substitute for sleep.''' Modafinil helps you stay awake but does not replace restorative sleep. Chronic sleep deprivation carries independent health risks regardless of wakefulness promotion.

'''Schedule IV.''' Modafinil is a controlled substance. Keep it secure, do not share it, and do not take more than prescribed. Psychological dependence can develop with misuse.

'''Warfarin / phenytoin users.''' If you take warfarin (Coumadin) or phenytoin (Dilantin), modafinil affects how those medicines work. Your prescriber may need to check levels or adjust doses.

'''OSA: keep using CPAP.''' Modafinil helps with residual daytime sleepiness but does not treat the breathing obstruction. CPAP is still essential for cardiovascular and cognitive protection.